VTRS · Viatris Inc.
$16.332026-07-21Sector: Healthcare; Industry: Drug Manufacturers - Specialty & Generic; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$101
+517.3% vs market
Base · active
$63
+283.0% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($46 · $101) Analysts Range ($12 · $22) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $15.4B | — | 16.4% | 45.0% | $1.4B | $1.1B | $2.5B | 9.6% | — | 3.6% | $39.0B | $0.05 | — |
| 2024.Q4 | $15.4B | 0.0% | 16.4% | 0.0% | $2.6B | $2.3B | $4.8B | 15.0% | — | 7.1% | $33.8B | $0.05 | — |
| 2025.Q1 | $14.7B | -4.5% | 0.2% | 3.4% | $32MM | $2.5B | $2.5B | 12.3% | — | 0.1% | $31.1B | $-0.54 | — |
| 2025.Q4 | $14.7B | 0.0% | 0.2% | 4.1% | $32MM | −$470MM | −$438MM | 11.7% | — | 0.1% | $29.9B | $-0.54 | — |
| 2026.Q1 | $14.6B | -1.2% | 3.2% | 45.0% | $253MM | −$962MM | −$709MM | 13.8% | — | 0.8% | $29.8B | $-0.25 | 41.7 |
| italics below = DCF projection · 10yr Rev CAGR: 3.1% |
| 2027.Q1 | $14.8B | +2.0% | 2.0% | 42.5% | $168MM | −$360MM | −$192MM | 12.7% | −$170MM | 0.6% | $30.1B | $0.04 | 408.2 |
| 2028.Q1 | $15.2B | +2.2% | 2.1% | 40.0% | $191MM | −$472MM | −$281MM | 12.3% | −$222MM | 0.6% | $30.6B | $0.05 | 326.6 |
| 2029.Q1 | $15.5B | +2.4% | 2.1% | 37.5% | $204MM | −$626MM | −$423MM | 11.8% | −$299MM | 0.7% | $31.2B | $0.05 | 326.6 |
| 2030.Q1 | $16.0B | +2.7% | 2.1% | 35.0% | $218MM | −$751MM | −$534MM | 11.4% | −$339MM | 0.7% | $32.0B | $0.06 | 272.2 |
| 2031.Q1 | $16.5B | +3.3% | 2.1% | 32.5% | $234MM | −$1.0B | −$773MM | 11.0% | −$441MM | 0.7% | $33.0B | $0.06 | 272.2 |
|
| Term. Yr+ | $20.5B | 4.1% | 84.4% | 20.0% | $13.8B | −$4.3B | $9.5B | 8.6% | $75.6B | 13.1% | — | — | — |
Active scenario IV: $63 (+283.0% vs market)